VIR vs. RXRX
Compare and contrast key facts about Vir Biotechnology, Inc. (VIR) and Recursion Pharmaceuticals, Inc. (RXRX).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: VIR or RXRX.
Performance
VIR vs. RXRX - Performance Comparison
Returns By Period
In the year-to-date period, VIR achieves a -33.00% return, which is significantly higher than RXRX's -38.74% return.
VIR
-33.00%
-11.90%
-40.72%
-28.53%
-12.06%
N/A
RXRX
-38.74%
-10.65%
-35.47%
-7.65%
N/A
N/A
Fundamentals
| VIR | RXRX | |
|---|---|---|
| Market Cap | $928.23M | $1.80B |
| EPS | -$3.93 | -$1.54 |
| Total Revenue (TTM) | $78.62M | $65.18M |
| Gross Profit (TTM) | $64.40M | $1.96M |
| EBITDA (TTM) | -$548.84M | -$366.27M |
Key characteristics
| VIR | RXRX | |
|---|---|---|
| Sharpe Ratio | -0.50 | -0.15 |
| Sortino Ratio | -0.50 | 0.38 |
| Omega Ratio | 0.94 | 1.04 |
| Calmar Ratio | -0.34 | -0.14 |
| Martin Ratio | -1.26 | -0.28 |
| Ulcer Index | 24.79% | 42.94% |
| Daily Std Dev | 61.88% | 82.24% |
| Max Drawdown | -91.89% | -88.97% |
| Current Drawdown | -91.89% | -85.39% |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Correlation
The correlation between VIR and RXRX is 0.42, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Risk-Adjusted Performance
VIR vs. RXRX - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Vir Biotechnology, Inc. (VIR) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
VIR vs. RXRX - Dividend Comparison
Neither VIR nor RXRX has paid dividends to shareholders.
Drawdowns
VIR vs. RXRX - Drawdown Comparison
The maximum VIR drawdown since its inception was -91.89%, roughly equal to the maximum RXRX drawdown of -88.97%. Use the drawdown chart below to compare losses from any high point for VIR and RXRX. For additional features, visit the drawdowns tool.
Volatility
VIR vs. RXRX - Volatility Comparison
Vir Biotechnology, Inc. (VIR) has a higher volatility of 29.68% compared to Recursion Pharmaceuticals, Inc. (RXRX) at 21.14%. This indicates that VIR's price experiences larger fluctuations and is considered to be riskier than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
VIR vs. RXRX - Financials Comparison
This section allows you to compare key financial metrics between Vir Biotechnology, Inc. and Recursion Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities